Nurix Therapeutics, Inc.
NRIX · Price history
Price at last available close
$27.26
+$3.58 (+15.12%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Nurix Therapeutics, Inc.
Primary reporting period: 2025-11-30 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
How they make money
Nurix Therapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through research and development collaboration agreements with pharmaceutical partners. These agreements typically involve upfront payments, research funding, and potential milestone payments or royalties upon the achievement of specific development, regulatory, or commercial goals for drug candidates discovered using its proprietary protein degradation platform.
Products & services
The company focuses on the discovery, development, and commercialization of targeted protein degradation medicines, including its lead clinical-stage BTK degrader, bexobrutideg, and various other pipeline programs targeting oncology and inflammatory diseases.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
For the fiscal year ended November 30, 2025, the company's revenue was highly concentrated, with a significant portion derived from a limited number of collaboration partners, specifically Gilead and Sanofi.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on various unnamed third-party vendors for clinical trial management, drug substance manufacturing, and laboratory services.Source
Business relationships & partnerships
- Gilead Sciences, Inc. — A strategic collaboration for the discovery and development of targeted protein degraders, including the IRAK4 degrader GS-6791.Source
- Sanofi — A strategic collaboration focused on the development of targeted protein degradation therapeutics for various disease indications.Source
Competitors
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-05-31.
Quarterly revenue fell 79.5% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Diluted weighted-average shares increased 32.4% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
23
Poor
Financial Strength
17
Business Quality / Moat
21
Management
40
Growth Quality
10
Risk / Durability
35
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for NRIX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving NRIX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can NRIX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does NRIX's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for NRIX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NRIX's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
27
Market Cap
$2.98B
P/E Ratio
-6.6
EPS
$-3.45
52-Week High
$28.23
52-Week Low
$9.00
Beta
1.82
Analyst Target
$34.00
Shares Outstanding
86.7M
Total Revenue
$36.8M
Total Debt
$58.1M
Dividend
No current dividend
Liquidation Value / Share
$4.65
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on NRIX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary AI-integrated discovery engine for protein degradation.
- +Strong balance sheet with significant cash and marketable securities.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on collaboration partners for revenue and development success.
- −Risks associated with clinical trial outcomes and regulatory approval processes.
- −Diluted weighted-average shares increased 32.4% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
22
Oct 8, 2026
Change
Unchanged
Current Score
22
Oct 9, 2026
Category Changes
NRIX score was unchanged.
Projected Score
Projected Score
20
Projected Change
-1.2 points
Preliminary comparable-period financial changes suggest decline of approximately 1.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$27.26
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +54.0%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.8M | $84.0M | $54.5M | $77.0M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | -$40.9M | $18.9M | $221.6M | $189.1M | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $77.7M | $65.1M | -$167.1M | -$112.2M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $332.2M | $308.2M | $221.6M | $189.1M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $57.0M | $52.7M | $45.9M | $42.9M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $438.9M | $350.8M | $45.9M | $42.9M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$324.4M | -$244.8M | -$176.9M | -$130.3M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$361.2M | -$285.7M | -$213.0M | -$155.1M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$341.6M | -$263.7M | -$193.3M | -$143.9M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$271K | $760K | $270K | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$341.4M | -$264.5M | -$193.6M | -$143.9M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.46 | $-3.05 | $-2.88 | $-2.65 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 111M | 86.67M | 67.12M | 54.34M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 111M | 86.67M | 67.12M | 54.34M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$9.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.81
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+12.0%
Cash Change
-19.7%
Margin Change
-891.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 79.5%. EPS increased 55.8%. Cash declined 19.7%. Total debt increased 12.0%. Net income margin declined by 891.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Rumor Mill · NRIX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial